California-based biopharmaceutical company Gilead Sciences, Inc. and New Jersey-based Merck have announced their agreement to develop and commercialise the long-acting HIV treatments lenacapavir and islatravir. The treatments combine
The post Gilead, Merck agreement to develop HIV treatments lenacapavir and islatravir appeared first on Pharmaceutical Business review.
This is not a CAPTIS article. Originally, it was published here.